ASAH1 and animal viral hepatitis: Additionally, potent first-generation small molecule aCDase inhibitors with submicromolar cellular activity have been reported (44), providing starting points for drug discovery aimed at fine-tuning checkpoint-ligand expression in chronic viral hepatitis or HIV.